Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque - 21/08/11
, Gary S. Mintz, MD a, Yoshio Kobayashi, MD b, David Jacoboff, MD a, Hilary Nierenberg, RN a, Hideo Takebayashi, MD a, Takenori Yasuda, MD a, Issam Moussa, MD a, George Dangas, MD, PhD a, Roxana Mehran, MD a, Alexandra J. Lansky, MD a, Edward M. Kreps, MD a, Michael Collins, MD a, Gregg W. Stone, MD a, Martin B. Leon, MD a, Jeffrey W. Moses, MD aRésumé |
Patients with acute coronary syndrome are at increased risk of acute and long-term events after stent implantation. We compared the impact of intravascular ultrasound detected plaque rupture on creatine kinase-MB (CK-MB) isoenzyme release and clinical outcomes by comparing 62 patients with ruptured plaques with 62 matched control patients who underwent stent implantation. Two thirds of the patients in each group presented with an acute coronary syndrome. There were no differences in procedural complications between groups, although patients with ruptured plaque had higher CK-MB elevation rates than those without ruptured plaque (1 to 3 times the upper limit of normal CK-MB, 35% vs 10%, p <0.001; >3 times the upper limit, 15% vs 2%, p = 0.02). Independent predictors of CK-MB elevation were presence of ruptured plaque (p = 0.03) and unstable angina (p = 0.04). Patients with ruptured plaque had higher composite rates of late events (target lesion revascularizations/myocardial infarctions/cardiac deaths) than controls (25% vs 9%, p = 0.03). These results were similar when only patients with acute coronary syndrome were studied. Plaque rupture morphology is associated with higher periprocedural CK-MB release and worse 1-year clinical outcome in patients treated with coronary stenting.
Le texte complet de cet article est disponible en PDF.Plan
Vol 95 - N° 3
P. 355-359 - février 2005 Retour au numéro
Article précédent
- In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction
- Lin Y. Chen, Ryan J. Lennon, J. Aaron Grantham, Peter B. Berger, Verghese Mathew, Mandeep Singh, David R. Holmes, Charanjit S. Rihal
- Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
- Prakash C. Deedwania, Donald B. Hunninghake, Harold E. Bays, Peter H. Jones, Valerie A. Cain, James W. Blasetto, for the STELLAR Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?